Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

101 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Liver Fibrosis Indices Predict the Severity of SARS-CoV-2 Infection.
Crudele L, Novielli F, Petruzzelli S, Battaglia S, Giuliano AFM, Melodia R, Morano CM, Dell'Aquila P, Moretti R, Castorani L, Salvia R, Inglese G, Susca N, dell'Olio L, Falcone F, Castaldo M, Matteis C, Sabbà C, Moschetta A. Crudele L, et al. Among authors: petruzzelli s. J Clin Med. 2022 Sep 13;11(18):5369. doi: 10.3390/jcm11185369. J Clin Med. 2022. PMID: 36143014 Free PMC article.
The bronchodilator effects of extrafine glycopyrronium added to combination treatment with beclometasone dipropionate plus formoterol in COPD: A randomised crossover study (the TRIDENT study).
Singh D, Schröder-Babo W, Cohuet G, Muraro A, Bonnet-Gonod F, Petruzzelli S, Hoffmann M, Siergiejko Z; TRIDENT study investigators. Singh D, et al. Among authors: petruzzelli s. Respir Med. 2016 May;114:84-90. doi: 10.1016/j.rmed.2016.03.018. Epub 2016 Mar 26. Respir Med. 2016. PMID: 27109816 Free article. Clinical Trial.
High strength extrafine pMDI beclometasone/formoterol (200/6 μg) is effective in asthma patients not adequately controlled on medium-high dose of inhaled corticosteroids.
Paggiaro P, Corradi M, Latorre M, Raptis H, Muraro A, Gessner C, Siergiejko Z, Scuri M, Petruzzelli S. Paggiaro P, et al. Among authors: petruzzelli s. BMC Pulm Med. 2016 Dec 9;16(1):180. doi: 10.1186/s12890-016-0335-9. BMC Pulm Med. 2016. PMID: 27938358 Free PMC article. Clinical Trial.
Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial.
Papi A, Vestbo J, Fabbri L, Corradi M, Prunier H, Cohuet G, Guasconi A, Montagna I, Vezzoli S, Petruzzelli S, Scuri M, Roche N, Singh D. Papi A, et al. Among authors: petruzzelli s. Lancet. 2018 Mar 17;391(10125):1076-1084. doi: 10.1016/S0140-6736(18)30206-X. Epub 2018 Feb 9. Lancet. 2018. PMID: 29429593 Clinical Trial.
Asthma progression and mortality: the role of inhaled corticosteroids.
O'Byrne P, Fabbri LM, Pavord ID, Papi A, Petruzzelli S, Lange P. O'Byrne P, et al. Among authors: petruzzelli s. Eur Respir J. 2019 Jul 18;54(1):1900491. doi: 10.1183/13993003.00491-2019. Print 2019 Jul. Eur Respir J. 2019. PMID: 31048346 Free PMC article. Review.
Single inhaler extrafine triple therapy in uncontrolled asthma (TRIMARAN and TRIGGER): two double-blind, parallel-group, randomised, controlled phase 3 trials.
Virchow JC, Kuna P, Paggiaro P, Papi A, Singh D, Corre S, Zuccaro F, Vele A, Kots M, Georges G, Petruzzelli S, Canonica GW. Virchow JC, et al. Among authors: petruzzelli s. Lancet. 2019 Nov 9;394(10210):1737-1749. doi: 10.1016/S0140-6736(19)32215-9. Epub 2019 Sep 30. Lancet. 2019. PMID: 31582314 Clinical Trial.
101 results